---
schema_version: "secwatch.filing_event.v1"
accession: "0001437749-23-034949"
form_type: "8-K"
ticker: "AURX"
cik: "0001091596"
company_name: "Nuo Therapeutics, Inc."
filed_at: "2023-12-20T23:59:59+00:00"
generated_at: "2026-06-07T09:43:24.516928+00:00"
event_type: "other"
sentiment: "neutral"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# Nuo Therapeutics raises $962,500 in private placement of 1.925M shares at $0.50/share

## Summary
- Sold 1,925,000 common shares at $0.50 each for gross proceeds of $962,500.
- Proceeds will be used for working capital purposes.
- Participants include director Scott Pittman ($300k), COO Clausen ($10k), and stockholder Sheedy ($75k).
- Total shares outstanding after placement: 44,241,516.
- Offering was exempt under Section 4(a)(2) of the Securities Act.

## SEC filing metadata
- accession: 0001437749-23-034949
- form_type: 8-K
- ticker: AURX
- cik: 0001091596
- company_name: Nuo Therapeutics, Inc.
- filed_at: 2023-12-20T23:59:59+00:00
- event_type: other
- sentiment: neutral
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: high
- sec_items: 1.01, 3.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1091596/000143774923034949/0001437749-23-034949-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1091596/000143774923034949/aurx20231219c_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001437749-23-034949
- JSON: https://secwatch.observer/filing/0001437749-23-034949.json
- Plain text: https://secwatch.observer/filing/0001437749-23-034949.txt

## Key facts
- Material Agreements
  Nuo Therapeutics, Inc. entered into Securities Purchase Agreement with certain accredited investors valued at $962,500 (effective 2023-12-18).
  - Action: entry
  - Agreement: equity purchase
  - Counterparty: certain accredited investors
  - Value: $962,500
  - Effective: 2023-12-18
  source text: On December 18, 2023, Nuo Therapeutics, Inc. (the “Company”) entered into a Securities Purchase Agreement, dated as of December 8, 2023, with certain accredited investors for the sale of 1,925,000 shares of the Company’s common stock, par value $0.0001 per share (the “Common Stock”) at a price of $0.50 per share for gross proceeds of $962,500 (the “Private Placement”).
  evidence_url: https://www.sec.gov/Archives/edgar/data/1091596/000143774923034949/0001437749-23-034949-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.